Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Analytical Scientist
  • Explore

    Explore

    • Latest
    • News & Research
    • Trends & Challenges
    • Keynote Interviews
    • Opinion & Personal Narratives
    • Product Profiles
    • App Notes
    • The Product Book

    Featured Topics

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy

    Issues

    • Latest Issue
    • Archive
  • Topics

    Techniques & Tools

    • Mass Spectrometry
    • Chromatography
    • Spectroscopy
    • Microscopy
    • Sensors
    • Data and AI

    • View All Topics

    Applications & Fields

    • Clinical
    • Environmental
    • Food, Beverage & Agriculture
    • Pharma and Biopharma
    • Omics
    • Forensics
  • People & Profiles

    People & Profiles

    • Power List
    • Voices in the Community
    • Sitting Down With
    • Authors & Contributors
  • Business & Education

    Business & Education

    • Innovation
    • Business & Entrepreneurship
    • Career Pathways
  • Events
    • Live Events
    • Webinars
  • Multimedia
    • Video
    • Content Hubs
Subscribe
Subscribe

False

The Analytical Scientist / Issues / 2026 / January / GLP1 Analysis Riding the Wave of Peptide Innovation
Pharma and Biopharma Pharma and Biopharma Trends Liquid Chromatography

GLP-1 Analysis: Riding the Wave of Peptide Innovation

The remarkable commercial success of GLP-1 receptor agonists is fueling investment, accelerating science, and creating new analytical challenges. Here, we outline the hurdles these peptides present, explore methods for impurity profiling and structural characterization, and consider strategies to keep pace with this fast-moving field.

By Amanda M. Guiraldelli, Piotr Alvarez, Koen Sandra 01/26/2026 12 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll
  • Top Institutions
  • Top Thought Leaders

Share

Top Institutions in Endocrinology and Metabolic Diseases

Ranking is based on known institutional leadership in diabetes and obesity research, peptide therapeutics innovation, clinical trial activity in GLP-1 RAs, and translational research in metabolic diseases.

  • #1

    Joslin Diabetes Center

    Boston, MA

    Joslin is a world-renowned leader in diabetes research and treatment, with extensive clinical trials and translational research focused on GLP-1 receptor agonists and peptide therapeutics for metabolic diseases.

    Key Differentiators

    • Endocrinology
    • Diabetes Research
    • Metabolic Diseases
  • #2

    Mayo Clinic

    Rochester, MN

    Mayo Clinic conducts extensive clinical research on obesity and diabetes treatments, including GLP-1 receptor agonists, with a strong focus on patient-centered therapeutic innovations and drug delivery systems.

    Key Differentiators

    • Endocrinology
    • Obesity Medicine
    • Clinical Pharmacology
  • #3

    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    UCSF is recognized for its cutting-edge research in metabolic diseases and peptide therapeutics, including pioneering studies on GLP-1 receptor agonists and novel drug delivery technologies.

    Key Differentiators

    • Endocrinology
    • Diabetes and Metabolism
    • Pharmacology
  • #4

    Massachusetts General Hospital (MGH)

    Boston, MA

    MGH has a robust research portfolio in diabetes and obesity, with significant contributions to clinical trials of GLP-1 receptor agonists and innovations in peptide drug delivery and molecular design.

    Key Differentiators

    • Endocrinology
    • Diabetes Research
    • Translational Medicine
  • #5

    Vanderbilt University Medical Center

    Nashville, TN

    Vanderbilt is known for its innovative clinical trials in metabolic diseases and peptide therapeutics, including GLP-1 receptor agonists, with a focus on novel drug delivery platforms and combination therapies.

    Key Differentiators

    • Endocrinology
    • Metabolic Disease Research
    • Clinical Trials

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Amanda M. Guiraldelli

Senior Scientist at RIC group, Belgium

More Articles by Amanda M. Guiraldelli

Piotr Alvarez

Senior Scientist, RIC group, Belgium

More Articles by Piotr Alvarez

Koen Sandra

Koen Sandra is CEO, RIC, Kortrijk, Belgium.

More Articles by Koen Sandra

False

Advertisement

Recommended

False

Related Content

Loading the Molecular Dice
Pharma and Biopharma
Loading the Molecular Dice

December 12, 2024

2 min read

How a framework for controlling molecular reactions at the atomic scale has potential implications for nanotechnology, pharmaceutical synthesis, and clean energy research

CD-MS: To Megadalton and Beyond
Pharma and Biopharma
CD-MS: To Megadalton and Beyond

October 1, 2024

10 min read

Charge-detection mass spectrometry (CD-MS) has extended the range of MS to gigadalton-sized viruses and polymers; and with a commercial instrument in development and exciting new applications in complex protein mixtures, maturity beckons

New NMR Technique Enables Direct Detection of Molecular Chirality
Pharma and Biopharma
New NMR Technique Enables Direct Detection of Molecular Chirality

October 1, 2024

1 min read

Researchers develop an NMR method to distinguish between enantiomers without the need for chiral agents

Mass Spec Imaging Meets Proteomics
Pharma and Biopharma
Mass Spec Imaging Meets Proteomics

October 2, 2024

2 min read

Researchers combine tissue imaging with proteomics to shed light on the neurotoxic effects associated with HIV medication Efavirenz treatment

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Analytical Scientist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.